EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›AFJK

AFJK

Aimei Health Technology Co., Ltd.

Next earnings Aug 11, 2026

Avoid
$27.54▲ +145.89%
over 1Y
L $8.00EODHDH $88.50
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W-8.9%
1M-31.1%
3M+13.0%
YTD-63.7%
1Y+145.9%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Avoid
Quality
F
Valuation
Fair value
Filings
Flagged
Avoid
Conviction
Horizon
Short (<3mo)

Pre-deal blank-check SPAC with negative equity trading ~$27 on a binary, repeatedly-delayed China-approval merger — speculation, not investment.

Net income (FY2025) $1.06M · FY2025

AFJK is not an operating business — it is a Cayman Islands blank-check (SPAC) shell whose entire FY2025 net income of $1.06M came from interest on cash in the Trust Account ($1,895,527 of trust interest less $835,759 of G&A), with the filing stating plainly: 'We have neither engaged in any operations nor generated any revenue to date.' Operating income is negative (-$836K) and operating cash flow is negative (-$565K). There is no revenue line, no margin, no franchise — the standard fundamentals lens does not apply. What matters is the trust, the deal, and the price relative to redemption value.

The balance sheet is hollowed out and stressed. Total assets collapsed 83.6% YoY to $12.1M (the signature of heavy shareholder redemptions, consistent with shares outstanding falling 48.3% to just 3.17M), while total liabilities jumped 169.5% to $4.06M and current liabilities surged 312.7% to $3.37M against essentially no current assets ($2.93K). Stockholders' equity is negative (-$4.06M), a liabilities/equity of -1.00x. The entire equity question hinges on one binary event: the proposed business combination with United Hydrogen.

Financials · annual, by fiscal year

Line itemFY24FY25
Revenue——
Gross profit——
Operating income-$1.06M-$836K
Net income$2.55M$1.06M
Diluted EPS——
Net margin——

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Piotroski F-Score3/6

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-48.3%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Recent disclosure tone has skewed negative — read the flagged items.
  1. 8-K Officer / director change2026-06-29

    Officer/director change (Item 5.02), likely tied to pending United Hydrogen close

  2. 10-Q Quarterly report2026-06-16

    Q1'26: pre-deal SPAC, interest income only; merger still awaiting CSRC approval

  3. 8-K New financial obligation2026-06-04

    Incurred new financial obligation—likely sponsor extension loan into trust

  4. 8-K Delisting notice2026-05-20

    Received Nasdaq continued-listing deficiency notice (Item 3.01); delisting risk

  5. 8-K New financial obligation2026-05-06

    New financial obligation incurred, likely sponsor extension funding for trust

  6. 10-K Annual report2026-05-04

    FY25 net income $1.06M (-59%); trust depleted by redemptions; close eyed May'26

  7. 8-K Delisting notice2026-04-21

    Received Nasdaq listing-deficiency notice (Item 3.01); delisting risk

  8. 8-K New financial obligation2026-04-07

    Incurred new financial obligation, likely sponsor loan to fund trust extension

  9. NT 10-K Late filing notice2026-04-01

    Notified SEC the FY25 10-K would be filed late (Form NT 10-K)

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-242026-06-29open ↗10-QPeriod ending 2026-03-312026-06-16open ↗8-KPeriod ending 2026-06-042026-06-04open ↗8-KPeriod ending 2026-05-192026-05-20open ↗8-KPeriod ending 2026-05-062026-05-06open ↗10-KPeriod ending 2025-12-312026-05-04open ↗8-KPeriod ending 2026-04-172026-04-21open ↗8-KPeriod ending 2026-04-072026-04-07open ↗NT 10-KPeriod ending 2025-12-312026-04-01open ↗8-KPeriod ending 2026-03-042026-03-04open ↗8-KPeriod ending 2026-02-122026-02-13open ↗SCHEDULE 13G/AFiling2026-02-12open ↗

Quality score

F
ValueGrowthProfitHealthMom.
Value—
GrowthF
Profitability—
Financial healthF
Momentum—
  • ✓Profitable (positive net income)
  • ✓Liabilities below 2× equity
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals · FY 2025

'24'25

■ revenue · ■ net income, by fiscal year

Net income$1.06M-58.5%
Operating income-$836K+21.5%
Total assets$12.1M-83.6%
Total liabilities$4.06M+169.5%
Stockholders' equity-$4.06M-174.9%
L/E: -1.00x

Frequently asked

Is Aimei Health Technology Co., Ltd. (AFJK) a buy?
AFJK currently carries a Avoid rating with 5/5 conviction, derived from its latest SEC filings. Pre-deal blank-check SPAC with negative equity trading ~$27 on a binary, repeatedly-delayed China-approval merger — speculation, not investment.
What is Aimei Health Technology Co., Ltd.'s quality score?
AFJK scores 27.333333333333332/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001979005, latest 10-Q filed 2026-06-16) · analysis by claude-code · as of 6/30/2026, 12:25:25 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2025-02-11
MIZUHO SECURITIES USA LLC
10% owner
Sell150K @ $10.86$1.63M
2023-12-01
Aimei Investment Ltd
10% owner
Buy332K @ $10.00$3.32M

Vs tracked universe

compare →

1192 tracked peers · median

EDGAR Score27 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 25.7